PT  - JOURNAL ARTICLE
AU  - Lang, David M.
TI  - The controversy over long-acting beta agonists: Examining the evidence
DP  - 2006 Nov 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 973--992
VI  - 73
IP  - 11
4099  - http://www.ccjm.org/content/73/11/973.short
4100  - http://www.ccjm.org/content/73/11/973.full
SO  - Cleve Clin J Med2006 Nov 01; 73
AB  - In the Salmeterol Multicenter Asthma Research Trial (SMART), patients receiving the long-acting beta agonist salmeterol—particularly African Americans—had a statistically significantly higher risk of fatal or potentially fatal asthma episodes. As a result, medications that contain salmeterol (Serevent, Advair) or formoterol (Foradil) carry a “black box warning.” However, the benefits of these drugs continue to outweigh the risks, if they are used appropriately.